Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)

Not Applicable

Completed

Brief Summary: This study aims to test the safety, efficacy and potential mechanism of action of the SinuSonic device on adults with upper respiratory infection (URI). SinuSonic is a medical device that utilizes sound and pressure combined with normal breathing. The study will have 2 aims. Aim 1 willdetermine if Sinusonic decreases the number of URIs experienced during an 8 week fall URI season. Subjects will use an active device (positive expiratory pressure and 128 Hz) or a sham device (no positive expiratory pressure and 1,000 Hz) for 1 min tid for 8 weeks. Aim 2 will determine if Sinusonic decreases the severity and duration of community acquired viral URIs. Subjects will use active or sham device as above.

Recruitment & Eligibility

Inclusion Criteria

Adults 18 years or older with no transient symptoms of any URI or allergies at baseline.

Exclusion Criteria

Any transient ENT condition that may impact upper airway to include acute sinusitis or otitis.
Any upper respiratory illness within last 2 weeks
TSS will be measured at baseline as described above and must be <9 for inclusion (Eccles etal).
Topical decongestant use in last week
Current nasal crusting or history of ulceration or perforation
History of severe nose bleeding within last 3 months
Known pregnancy
Immunosuppressed condition or on immune modulating medications such as prednisone or chemotherapy
Allergic sensitivity to silicone or any other component of device
Inability to read and understand English
Inability to perform treatment due to underlying medical condition

Arm && Interventions

Group	Intervention	Description
Sham	Sham SinuSonic Device	Sham SinuSonic device used for 1 min three times a day for 8 weeks.
SinuSonic Device	SinuSonic Device	SinuSonic device used for 1 min three times a day for 8 weeks.

Primary Outcome Measures

Name	Time	Method
Total Symptoms Score (TSS)	60 Days	The Total Symptom Score (TSS) was based on the severity of each of upper respiratory infection (URI) symptom. The TSS includes 9 symptoms: Lost sense of smell/taste, sneezing, runny nose or thick nasal discharge, nasal obstruction or congestion, sore throat, cough headache, maliase, and chilliness. The severity of URI symptoms was scored on a symptom severity scale (0 = not at all; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms) Minimum score=0; maximum score=27.

Secondary Outcome Measures